Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr 14;72(15):1310-5.
doi: 10.1212/01.wnl.0000341308.73506.b7. Epub 2008 Dec 17.

Treatment effects for which shift or binary analyses are advantageous in acute stroke trials

Affiliations

Treatment effects for which shift or binary analyses are advantageous in acute stroke trials

Jeffrey L Saver et al. Neurology. .

Abstract

Background: In acute stroke trials, functional outcome may be analyzed by dichotomizing ordinal outcome scales or by evaluating the entire scale range (shift analysis). The conditions under which shift or binary analysis will be more efficient have not been previously well delineated.

Methods: Model randomized clinical trials employing the modified Rankin Scale of global handicap were constructed to reflect 1) mild benefits experienced across all ranges of stroke severity (neuroprotective effect), 2) substantial benefits across all ranges of stroke severity (early recanalization effect), 3) substantial benefits across wide range of stroke severity but with limited ability to achieve fully normal outcome (late recanalization effect), 4) benefits clustered at unexpected health state transitions.

Results: In neuroprotective models, shift analysis was the most efficient technique in detecting a treatment effect. In the early recanalization models, dichotomization at excellent outcome and shift analysis were of comparable efficiency, both superior to dichotomization at good outcome. In the late recanalization models, dichotomization at good outcome performed best, shift analysis less well, and dichotomization at excellent outcome poorly. In the unexpected benefits model, shift analysis substantially outperformed dichotomization analyses. These patterns held among the seven actual acute trials reporting full range Rankin outcomes and showing treatment benefit identified in the literature.

Conclusions: The pattern of treatment effect of the intervention determines whether shift analysis or simple dichotomized analysis will be more efficient. Shift analysis is especially advantageous when treatments confer a relatively uniform, mild benefit to patients over a wide range of stroke severities or confer benefits at unexpected but clinically important health state transitions.

PubMed Disclaimer

Figures

None
Figure 1 The four analyzed treatment effect models For each, the staircase schematic shows the pattern of the treatment effect, the upper table shows the percentile distribution of outcomes among the six Rankin levels in the treatment and control groups, and the bottom table shows the sample size required by each of the endpoint analytic techniques.
None
Figure 2 Treatment effect profile maps In individual bar graphs, each bar represents the absolute difference in the percent of patients achieving a good outcome under active treatment vs control, when good outcome is defined as modified Rankin scale (mRS) = 0 (column 1), mRS = 0–1 (column 2), mRS = 0–2 (column 3), mRS = 0–3 (column 4), mRS = 0–4 (column 5). In the overall figure, the four bar graphs in A are the treatment effect profile maps for the four models. The four bar graphs in B are the treatment effect profile maps for actual clinical trials that resemble each of the prototypical models.

Comment in

References

    1. Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588–600. - PubMed
    1. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495–505. - PMC - PubMed
    1. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke 2007;38:3055–3062. - PubMed
    1. Bath PM, Gray LJ, Collier T, Pocock S, Carpenter J. Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials. Stroke 2007;38:1911–1915. - PubMed
    1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587. - PubMed

Publication types